Biochemical recurrence after localized treatment

被引:19
作者
Amling, Christopher L. [1 ]
机构
[1] Univ Alabama Birmingham, Div Urol, Birmingham, AL 35294 USA
关键词
D O I
10.1016/j.ucl.2005.12.002
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The quoted incidence of biochemical recurrence (BCR) after localized treatment varies significantly and depends on numerous well-known prognostic factors; however, it likely occurs in at least 30%-40% of patients who receive localized treatment. Because the clinical significance of BCR is often unclear, and depends in many cases on unknown factors, it is difficult to select the best treatment and determine when best to institute that therapy. This review examines some of the issues associated with BCR and attempts to shed some light on this common but controversial clinical scenario. Some treatment strategies discussed in this article include salvage radiotherapy after radical prostatectomy, salvage therapy after radiotherapy, and hormonal therapy.
引用
收藏
页码:147 / +
页数:14
相关论文
共 79 条
[1]   Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation [J].
Albertsen, PC ;
Hanley, JA ;
Penson, DF ;
Fine, J .
JOURNAL OF UROLOGY, 2004, 171 (06) :2221-2225
[2]   Defining prostate specific antigen progression after radical prostatectomy: What is the most appropriate cut point? [J].
Amling, CL ;
Bergstralh, EJ ;
Blute, ML ;
Slezak, JM ;
Zincke, H .
JOURNAL OF UROLOGY, 2001, 165 (04) :1146-1151
[3]   TREATMENT WITH FINASTERIDE FOLLOWING RADICAL PROSTATECTOMY FOR PROSTATE-CANCER [J].
ANDRIOLE, G ;
LIEBER, M ;
SMITH, J ;
SOLOWAY, M ;
SCHROEDER, F ;
KADMON, D ;
DEKERNION, J ;
RAJFER, J ;
BOAKE, R ;
CRAWFORD, D ;
RAMSEY, E ;
PERREAULT, J ;
TRACHTENBERG, J ;
FRADET, T ;
BLOCK, N ;
MIDDLETON, R ;
NG, J ;
FERGUSON, D ;
GORMLEY, G .
UROLOGY, 1995, 45 (03) :491-497
[4]  
[Anonymous], 1997, Br J Urol, V79, P235
[5]  
[Anonymous], 1997, Int J Radiat Oncol Biol Phys, V37, P1035
[6]   Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: The first 10 years [J].
Anscher, MS ;
Clough, R ;
Dodge, R .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 48 (02) :369-375
[7]   Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen [J].
Bander, NH ;
Trabulsi, EJ ;
Kostakoglu, L ;
Yao, D ;
Vallabhajosula, S ;
Smith-Jones, P ;
Joyce, MA ;
Milowsky, M ;
Nanus, DM ;
Goldsmith, SJ .
JOURNAL OF UROLOGY, 2003, 170 (05) :1717-1721
[8]   Permanent brachytherapy as salvage treatment for recurrent prostate cancer [J].
Beyer, DC .
UROLOGY, 1999, 54 (05) :880-883
[9]   Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy [J].
Bianco, FJ ;
Scardino, PT ;
Stephenson, AJ ;
DiBlasio, CJ ;
Fearn, PA ;
Eastham, JA .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 62 (02) :448-453
[10]   Update on magnetic resonance imaging, ProstaScint, and novel imaging in prostate cancer [J].
Brassell, SA ;
Rosner, IL ;
McLeod, DG .
CURRENT OPINION IN UROLOGY, 2005, 15 (03) :163-166